Does the media favor ABOS or DBVT?

In the previous week, Acumen Pharmaceuticals and Acumen Pharmaceuticals both had 3 articles in the media. DBV Technologies' average media sentiment score of 1.07 beat Acumen Pharmaceuticals' score of 0.63 indicating that DBV Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ABOS or ACRS?

In the previous week, Aclaris Therapeutics had 3 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 6 mentions for Aclaris Therapeutics and 3 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.63 beat Aclaris Therapeutics' score of 0.59 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ABOS or CTMX?

In the previous week, CytomX Therapeutics had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 4 mentions for CytomX Therapeutics and 3 mentions for Acumen Pharmaceuticals. CytomX Therapeutics' average media sentiment score of 1.45 beat Acumen Pharmaceuticals' score of 0.63 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer FDMT or ABOS?

In the previous week, 4D Molecular Therapeutics had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 4 mentions for 4D Molecular Therapeutics and 3 mentions for Acumen Pharmaceuticals. 4D Molecular Therapeutics' average media sentiment score of 1.35 beat Acumen Pharmaceuticals' score of 0.63 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acumen Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PHAR or ABOS?

In the previous week, Pharming Group had 8 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 11 mentions for Pharming Group and 3 mentions for Acumen Pharmaceuticals. Pharming Group's average media sentiment score of 1.09 beat Acumen Pharmaceuticals' score of 0.63 indicating that Pharming Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acumen Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Acumen Pharmaceuticals (ABOS) Competitors

$2.92 +0.06 (+2.10%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.91 -0.01 (-0.34%)

As of 09/11/2026 07:30 PM Eastern

Compare

ABOS vs. DBVT, ACRS, CTMX, FDMT, and PHAR

Should you buy Acumen Pharmaceuticals stock or one of its competitors? Acumen Pharmaceuticals's main competitors and comparable companies include DBV Technologies (DBVT), Aclaris Therapeutics (ACRS), CytomX Therapeutics (CTMX), 4D Molecular Therapeutics (FDMT), and Pharming Group (PHAR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Acumen Pharmaceuticals compare to DBV Technologies?

Acumen Pharmaceuticals (NASDAQ:ABOS) and DBV Technologies (NASDAQ:DBVT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Acumen Pharmaceuticals currently has a consensus price target of $8.00, suggesting a potential upside of 173.97%. DBV Technologies has a consensus price target of $48.50, suggesting a potential upside of 309.28%. Given DBV Technologies' stronger consensus rating and higher possible upside, analysts plainly believe DBV Technologies is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Acumen Pharmaceuticals and Acumen Pharmaceuticals both had 3 articles in the media. DBV Technologies' average media sentiment score of 1.07 beat Acumen Pharmaceuticals' score of 0.63 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Acumen Pharmaceuticals has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.95, suggesting that its stock price is 195% less volatile than the broader market.

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 1.1% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Acumen Pharmaceuticals has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. DBV Technologies' return on equity of -119.33% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

Acumen Pharmaceuticals has higher earnings, but lower revenue than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A
DBV Technologies	$5.64M	132.11	-$146.95M	-$3.51	N/A

Summary

Acumen Pharmaceuticals and DBV Technologies tied by winning 7 of the 14 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Aclaris Therapeutics?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

In the previous week, Aclaris Therapeutics had 3 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 6 mentions for Aclaris Therapeutics and 3 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.63 beat Aclaris Therapeutics' score of 0.59 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aclaris Therapeutics has higher revenue and earnings than Acumen Pharmaceuticals. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A
Aclaris Therapeutics	$7.83M	95.00	-$64.92M	-$0.58	N/A

Acumen Pharmaceuticals has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -921.50%. Aclaris Therapeutics' return on equity of -61.65% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%

Acumen Pharmaceuticals has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 10.2% of Acumen Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Acumen Pharmaceuticals presently has a consensus target price of $8.00, suggesting a potential upside of 173.97%. Aclaris Therapeutics has a consensus target price of $11.33, suggesting a potential upside of 113.03%. Given Acumen Pharmaceuticals' higher probable upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

Summary

Aclaris Therapeutics beats Acumen Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to CytomX Therapeutics?

Acumen Pharmaceuticals (NASDAQ:ABOS) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, CytomX Therapeutics had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 4 mentions for CytomX Therapeutics and 3 mentions for Acumen Pharmaceuticals. CytomX Therapeutics' average media sentiment score of 1.45 beat Acumen Pharmaceuticals' score of 0.63 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Acumen Pharmaceuticals currently has a consensus price target of $8.00, indicating a potential upside of 173.97%. CytomX Therapeutics has a consensus price target of $11.90, indicating a potential upside of 261.70%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

CytomX Therapeutics has higher revenue and earnings than Acumen Pharmaceuticals. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A
CytomX Therapeutics	$76.20M	9.41	-$17.37M	-$0.50	N/A

Acumen Pharmaceuticals has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market.

Acumen Pharmaceuticals has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -435.21%. CytomX Therapeutics' return on equity of -38.46% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

Summary

CytomX Therapeutics beats Acumen Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to 4D Molecular Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

4D Molecular Therapeutics currently has a consensus price target of $29.63, indicating a potential upside of 124.94%. Acumen Pharmaceuticals has a consensus price target of $8.00, indicating a potential upside of 173.97%. Given Acumen Pharmaceuticals' higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Acumen Pharmaceuticals has lower revenue, but higher earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	8.54	-$140.11M	-$2.63	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A

In the previous week, 4D Molecular Therapeutics had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 4 mentions for 4D Molecular Therapeutics and 3 mentions for Acumen Pharmaceuticals. 4D Molecular Therapeutics' average media sentiment score of 1.35 beat Acumen Pharmaceuticals' score of 0.63 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acumen Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

4D Molecular Therapeutics has a beta of 2.74, suggesting that its share price is 174% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

Acumen Pharmaceuticals has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -194.74%. 4D Molecular Therapeutics' return on equity of -41.33% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%

Summary

4D Molecular Therapeutics beats Acumen Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Pharming Group currently has a consensus price target of $38.67, suggesting a potential upside of 244.93%. Acumen Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 173.97%. Given Pharming Group's higher probable upside, research analysts clearly believe Pharming Group is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Pharming Group has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market.

Pharming Group has a net margin of 2.51% compared to Acumen Pharmaceuticals' net margin of 0.00%. Pharming Group's return on equity of 3.40% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%

Pharming Group has higher revenue and earnings than Acumen Pharmaceuticals. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.11	$2.85M	$0.12	93.42
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A

In the previous week, Pharming Group had 8 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 11 mentions for Pharming Group and 3 mentions for Acumen Pharmaceuticals. Pharming Group's average media sentiment score of 1.09 beat Acumen Pharmaceuticals' score of 0.63 indicating that Pharming Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acumen Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Pharming Group beats Acumen Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get Acumen Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABOS vs. The Competition

Export

Metric	Acumen Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$211.17M	$3.86B	$7.16B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-1.79	8.41	214.39	20.85
Price / Sales	N/A	1,378.88	633.80	90.72
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	2.52	15.12	10.33	6.21
Net Income	-$121.33M	-$22.86M	$3.50B	$358.54M
7 Day Performance	-8.18%	-4.34%	-3.32%	-2.35%
1 Month Performance	14.51%	0.54%	-0.53%	-3.23%
1 Year Performance	121.21%	40.74%	23.51%	8.79%

Acumen Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABOS Acumen Pharmaceuticals	2.312 of 5 stars	$2.92 +2.1%	$8.00 +174.0%	+121.2%	$211.17M	N/A	N/A	20	News Coverage Gap Up
DBVT DBV Technologies	3.461 of 5 stars	$13.41 -3.0%	$48.50 +261.7%	+20.1%	$843.22M	$5.64M	N/A	80	News Coverage Positive News Analyst Forecast
ACRS Aclaris Therapeutics	2.3091 of 5 stars	$6.03 -0.3%	$11.33 +87.9%	+172.8%	$843.12M	$7.83M	N/A	100	News Coverage Positive News
CTMX CytomX Therapeutics	2.8876 of 5 stars	$3.70 +10.1%	$11.90 +221.6%	+64.5%	$806.23M	$76.20M	N/A	170	Positive News Gap Down
FDMT 4D Molecular Therapeutics	3.7479 of 5 stars	$14.48 +2.6%	$29.63 +104.6%	+93.4%	$799.88M	$85.21M	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABOS) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acumen Pharmaceuticals (ABOS) Competitors

ABOS vs. DBVT, ACRS, CTMX, FDMT, and PHAR

How does Acumen Pharmaceuticals compare to DBV Technologies?

Summary

How does Acumen Pharmaceuticals compare to Aclaris Therapeutics?

Summary

How does Acumen Pharmaceuticals compare to CytomX Therapeutics?

Summary

How does Acumen Pharmaceuticals compare to 4D Molecular Therapeutics?

Summary

How does Acumen Pharmaceuticals compare to Pharming Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS vs. The Competition

Acumen Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acumen Pharmaceuticals (ABOS) Competitors

ABOS vs. DBVT, ACRS, CTMX, FDMT, and PHAR

How does Acumen Pharmaceuticals compare to DBV Technologies?

Do analysts prefer ABOS or DBVT?

Does the media favor ABOS or DBVT?

Which has more volatility and risk, ABOS or DBVT?

Do insiders and institutionals hold more shares of ABOS or DBVT?

Is ABOS or DBVT more profitable?

Which has higher valuation and earnings, ABOS or DBVT?

Summary

How does Acumen Pharmaceuticals compare to Aclaris Therapeutics?

Does the media favor ABOS or ACRS?

Which has higher earnings and valuation, ABOS or ACRS?

Is ABOS or ACRS more profitable?

Which has more risk and volatility, ABOS or ACRS?

Do insiders & institutionals have more ownership in ABOS or ACRS?

Do analysts recommend ABOS or ACRS?

Summary

How does Acumen Pharmaceuticals compare to CytomX Therapeutics?

Do insiders & institutionals believe in ABOS or CTMX?

Does the media favor ABOS or CTMX?

Do analysts recommend ABOS or CTMX?

Which has higher valuation & earnings, ABOS or CTMX?

Which has more volatility and risk, ABOS or CTMX?

Is ABOS or CTMX more profitable?

Summary

How does Acumen Pharmaceuticals compare to 4D Molecular Therapeutics?

Do analysts recommend FDMT or ABOS?

Which has better valuation and earnings, FDMT or ABOS?

Does the media prefer FDMT or ABOS?

Do insiders and institutionals have more ownership in FDMT or ABOS?

Which has more risk & volatility, FDMT or ABOS?

Is FDMT or ABOS more profitable?

Summary

How does Acumen Pharmaceuticals compare to Pharming Group?

Do insiders & institutionals hold more shares of PHAR or ABOS?

Do analysts rate PHAR or ABOS?

Which has more risk & volatility, PHAR or ABOS?

Is PHAR or ABOS more profitable?

Which has higher earnings & valuation, PHAR or ABOS?

Does the media refer more to PHAR or ABOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS vs. The Competition

Acumen Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools